Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.
INSERM 643, Institut de Transplantation et de Recherche en Transplantation (ITERT), Universite de Nantes, France.
Hoa L
HL
Mai
Anne
A
Cesbron
Sophie
S
Brouard
Gilles
G
Blanchol
Diego
D
Cantarovich
Jacques
J
Dantal
Maryvonne
M
Hourmant
Marie
M
Lino
Aurelie
A
Meurette
Morgane
M
Gosselin
Odette
O
Abbadie
Jean-Paul
JP
Soulillou
Magali
M
Giral
D000305:Adrenal Cortex Hormones / Q000097:blood; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006650:Histocompatibility Testing; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000188:drug therapy; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010951:Plasma Exchange; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D000069283:Rituximab; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001897:Boronic Acids; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D011480:Protease Inhibitors; D011719:Pyrazines; D000069283:Rituximab; D000069286:Bortezomib